CRDO
From Preclinical to Commercialization: A CRDO Approach to Accelerating Biologic Development
Matthias Lucke, Ph.D.; Ivonne Stelzl, Ph.D.
Coriolis Pharma
PAO-08-25-CL-02Aug 04, 2025
Delivery Devices
From Prefilled Syringes to On-body Devices – How Optimized Biologics Formulations Improve Patient Adherence
Eva Keilhauer, Ph.D.; Andreas Stelzl, Ph.D.
Coriolis Pharma
PAO-06-25-CL-07Jul 08, 2025
Formulation
The Importance of a Robust Formulation for Long-Term Drug Development Success
Michaela Breitsamer, Dr. rer. nat.
Coriolis Pharma
PAO-06-25-CL-04Jun 30, 2025
Analytical
Leveraging Advanced GMP Release and Stability Testing Methods to Accelerate New Drug Development
Carsten Kroeger, Dr. rer. nat.; Gerhard Sax, Dr. rer. nat.
Coriolis Pharma
PAO-04-25-CL-03Apr 15, 2025
Particle Analysis
Advancing Subvisible Particle Characterization with Artificial Intelligence
Daniel Weinbuch, Ph.D.
Coriolis Pharma
PAO-03-25-CL-02Mar 11, 2025
Lyophilization
Ensuring Biologic Stability with Tailored and Cutting-Edge Lyophilization Solutions
Brecht Vanbillemont, Dr.; Lisa Besslich, Dr. Rer. Nat.
Coriolis Pharma
PAO-02-25-CL-12Feb 18, 2025
Developability
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.
Coriolis Pharma
PAO-01-25-CL-12Jan 27, 2025
Particle ID
Leveraging Formulation Development Experience for Effective Particle Identification
Jörg Müller, Ph.D.
Coriolis Pharma
PAO-10-24-CL-10Nov 18, 2024
Commercialization
Development Strategies for Overcoming Commercialization Challenges
Matthias Lucke, Ph.D.
Coriolis Pharma
PAO-09-24-CL-10Sep 17, 2024
IND Enablement
IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"
Johannes Clemens
Coriolis Pharma
PAO-08-24-CL-07Aug 16, 2024
CRDO
Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
Silvia Steyrer-Gruber
Coriolis Pharma
PAO-07-24-CL-05Jul 16, 2024
Monoclonal Antibodies
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies
Coriolis Pharma
PR-05-24-NI-02Jun 18, 2024